Clinical Policy: Lanreotide (Somatuline Depot and Unbranded)

Reference Number: LA.PHAR.391
Effective Date: 04.28.21
Last Review Date: ~~04.05.24~~12.1~~0~~9.24 Coding Implications
Line of Business: Medicaid Revision Log

See Important Reminder **at the end of this policy for important regulatory and legal information.**

****Please note: This policy is for medical benefit****

Description
Lanreotide (Somatuline® Depot) and unbranded lanreotide are a somatostatin analog.

FDA Approved Indication(s)
Somatuline Depot and unbranded lanreotide are indicated for:

- Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy
- Treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival

~~Somatuline Depot is additionally indicated for:~~

- Treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that unbranded lanreotide and Somatuline Depot ~~is~~are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Acromegaly (must meet all)**:**

1. Diagnosis of acromegaly as evidenced by one of the following (a or b):
   a. Pre-treatment insulin-like growth factor-I (IGF-I) level above the upper limit of normal based on age and gender for the reporting laboratory;
   b. Serum growth hormone (GH) level ≥ 1 µg/~~ml~~L after a 2-hour oral glucose tolerance test;
2. Prescribed by or in consultation with an endocrinologist;
3. Age ≥ 18 years;
4. Inadequate response to surgical resection or pituitary irradiation (*see Appendix D*), or member is not a candidate for such treatment;
5. Request is for either Somatuline Depot or unbranded lanreotide;

6. Failure of Sandostatin® LAR Depot, unless contraindicated or clinically adverse effects are experienced;
   ~~~~Prior authorization may be required for Sandostatin LAR Depot*
7. Dose does not exceed 120 mg every 4 weeks.

Approval duration: 6 months

B. Carcinoid Syndrome (must meet all)**:**

1. Diagnosis of carcinoid syndrome (associated with NETs of the gastrointestinal tract, lung, and thymus, otherwise known as carcinoid tumors);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Request is for either Somatuline Depot or unbranded lanreotide;
~~Member meets one of the following (a or b):~~
5. Failure of Sandostatin LAR Depot, unless contraindicated, clinically adverse effects are experienced;
   **Prior authorization may be required for Sandostatin LAR Depot*
   ~~Request is for treatment associated cancer for a State with regulations against step therapy in certain oncology settings *(see Appendix E)*;~~

~~5.~~6.Request meets one of the following (a or b):*
   a. Dose does not exceed 120 mg every 4 weeks;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).
      **Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6 months

C. Neuroendocrine Tumors (must meet all)**:**

1. Diagnosis of one of the following (a, b, c, or ~~c~~d):
   a. GEP-NET (*see Appendix D for tumor types*), and:
      i. If insulinoma, disease is somatostatin receptor (SSTR)-positive;
   b. Pheochromocytoma or paraganglioma (adrenal NETs);
   c. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH);
   ~~c.~~d.One of the following NETs which is SSTR-positive or has hormonal symptoms (i, ii, or iii):
      i. Thymic NET;
      ii. ~~Bronchopulmonary~~Lung NET;
      iii. Grade 3 NET with favorable biology (i.e., relatively low Ki-67 [< 55%] slow growing, or SSTR-positive based PET imaging);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Request is for either Somatuline Depot or unbranded lanreotide;
~~Member meets one of the following (a or b):~~
~~a.~~5.Failure of Sandostatin~~®~~ LAR Depot, unless contraindicated ~~or~~, clinically adverse effects are experienced;
   ~~~~Prior authorization may be required for Sandostatin LAR Depot*
   ~~Request is for treatment associated cancer for a State with regulations against step therapy in certain oncology settings *(see Appendix E)*;~~

Formatted

Formatted

~~5.~~6. Request meets one of the following (a or b):*
   a. Dose does not exceed 120 mg every 4 weeks;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6 months

D. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

II. Continued Therapy

A. Acromegaly (must meet all)**:**
   a. Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy (*see Appendix D*);
3. If request is for a dose increase, new dose does not exceed 120 mg every 4 weeks.

Approval duration: 12 months

B. Carcinoid Syndrome and Neuroendocrine Tumors (must meet all)**:**
1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving unbranded lanreotide or Somatuline Depot for a covered indication and has received this medication for at least 30 days;
2. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose does not exceed 120 mg every 4 weeks;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration
GEP: gastroenteropancreatic
GH: growth hormone
IGF-I: insulin-like growth factor
NET: neuroendocrine tumor
SSTR: somatostatin receptor

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Octreotide acetate (Sandostatin LAR deport) (IM)	**Acromegaly:** 20-40 mg IM every 4 weeks **Carcinoid tumors:** 20-30 mg IM every 4 weeks **Neuroendocrine Tumors:** 20-30 mg IM every 4 weeks	See dosing regimen

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to lanreotide
- Boxed warning(s): none reported

Appendix D: General Information

- Response to acromegaly therapy (e.g., somatostatin analogs, surgical resection, pituitary irradiation) may include:
  - Improved GH or IGF-I serum concentrations
  - Improved tumor mass control
- NCCN guidelines - Neuroendocrine and Adrenal Tumors
  - GEP-NETs
    - Gastrointestinal tract tumors include the appendix, stomach, colon and rectum, duodenum, gastric, jejunum and ileum.
    - Pancreatic tumors include insulinoma, gastrinoma, VIPoma (vasoactive intestinal polypeptide), glucagonoma, and nonfunctioning pancreatic tumors.
      - For patients with insulinoma, lanreotide should be considered only if the tumor expresses SSTR.
  - ~~Patients experiencing~~If clinically significant disease progression ~~on lanreotide should continue,~~ treatment with lanreotide ~~if the tumor is~~ should be discontinued for non-functional~~. Lanreotide~~ tumors and continued in patients with functional tumors and may be used in combination with ~~other systemic therapy~~any of the subsequent options.

Appendix E: States with Regulations against Redirections in Cancer

State	Step Therapy Prohibited?	Notes
FL	Yes	For stage 4 metastatic cancer and associated conditions.
GA	Yes	For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.
IA	Yes	For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.
LA	Yes	For stage 4 advanced, metastatic cancer or associated conditions. Exception if "clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.
MS	Yes	**Applies to HIM requests only** For advanced metastatic cancer and associated conditions
NV	Yes	Stage 3 and stage 4 cancer patients for a prescription drug to treat the cancer or any symptom thereof of the covered person
OH	Yes	**Applies to HIM requests only** For stage 4 metastatic cancer and associated conditions
OK	Yes	**Applies to HIM requests only** For advanced metastatic cancer and associated conditions
PA	Yes	For stage 4 advanced, metastatic cancer
TN	Yes	For advanced metastatic cancer and associated conditions
TX	Yes	For stage 4 advanced, metastatic cancer and associated conditions

V. Dosage and Administration*

Indication	Dosing Regimen	Maximum Dose
Acromegaly	Initial: 90 mg SC every 4 weeks for 3 months Maintenance: 90 to 120 mg SC every 4 weeks Dose should be adjusted according to reduction in serum GH or IGF-1 levels and/or changes in symptoms.	Maintenance: 120 mg every 4 weeks
GEP-NETs, carcinoid syndrome	120 mg SC every 4 weeks If patients are being treated with Somatuline Depot for both GEP-NET and carcinoid syndrome, do not administer an additional dose	120 mg every 4 weeks

**Intended for administration by a healthcare provider*

VI. Product Availability

Single-dose prefilled syringes: 60 mg/0.2 mL, 90 mg/0.3 mL, 120 mg/0.5 mL

VII. References

1. Somatuline Depot Prescribing Information. Signes, France: Ipsen Pharma Biotech; ~~February 2023.~~July 2024. Available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/~~2023/022074s026lbl~~2024/022074s032lbl.pdf. Accessed ~~August 4, 2023~~July 25, 2024.
2. Lanreotide Prescribing Information. Warren, NJ: Cipla USA. Inc.; ~~December 2021.~~September 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/~~2021/215395s000lbl~~2024/215395s007lbl.pdf. Accessed ~~August 17, 2023.~~October 10, 2024.
3. Melmed S, Bronstein MD, Chanson P. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018 Sep;14(9):552-561. doi: 10.1038/s41574-018-0058-5.
4. Katznelson L, Laws Jr. ER, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933-3951.
5. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed ~~August 4, 2023~~October 10, 2024.
6. National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors Version ~~1.2023~~2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed ~~August 4, 2023.~~October 10, 2024.
7. Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021; 24: 1-13.
8. Guistina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020; 21(4): 667-678.
9. Giustina A, Biermasz N, Casanueva FF, et al; Acromegaly Consensus Group (ACG). Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024 Feb;27(1):7-22. doi: 10.1007/s11102-023-01360-1.

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1930	Injection, lanreotide, 1 mg
J1932	Injection, lanreotide, (cipla), 1 mg
~~C9399~~J3490	Unclassified drugs ~~or biologicals~~

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created	01.21	04.28.21
For acromegaly, added confirmatory diagnostic requirements (IGF-I or GH) per PS/ES practice guidelines; per NCCN, specified that thymic/ bronchopulmonary NETs and insulinomas must be SSTR-positive or have hormonal symptoms and added that any grade 3 NETs with favorable biology are also coverable~~.~~	06.25.23	10.05.23

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Template changes applied to other diagnoses/indications and continued therapy section. References reviewed and updated. Added redirection to Sandostatin LAR depot.		
Annual review; Added unbranded lanreotide acetate formulation; updated neuroendocrine tumor criteria Grade 3 NET examples and pancreatic tumor examples in Appendix D to align with current NCCN Neuroendocrine Tumors fo the Gastrointestinal Tract, Lung, and Thymus guideline and NCCN compendium; references reviewed and updated.	04.05.24	07.10.24
For acromegaly, revised initial criteria from "(GH) level ≥ 1 µg/mL" to "(GH) level ≥ **1 µg/L**" per PS/ES practice guidelines and ACG;- revised "bronchopulmonary NET" to "lung NET" per NCCN compendium and guideline; updated Appendix D "NCCN guidelines - Neuroendocrine and Adrenal Tumors" supplemental information; removed inactive HCPCS code C9399 and added HCPCS code J3490; references reviewed and updated. For unbranded lanreotide, added newly approved carcinoid syndrome indication to FDA Approved Indication(s) section.	12.1~~09~~.24	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the

requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.